StockNews.AI
ALNY
StockNews.AI
152 days

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

1. ALNY received FDA approval for AMVUTTRA® to treat ATTR-CM. 2. This approval aims to reduce cardiovascular risks in patients.

2m saved
Insight
Article

FAQ

Why Very Bullish?

FDA approval significantly boosts ALNY's market potential, similar to past approvals increasing share prices for biotech firms like Amgen.

How important is it?

FDA approvals historically enhance biotech company valuations; this could lead to increased sales and partnerships.

Why Short Term?

Immediate market response expected due to FDA approval driving investor confidence and stock price.

Related Companies

AMGNREGNVRTX
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu.

Related News